CN110770252A - 抗p53抗体 - Google Patents

抗p53抗体 Download PDF

Info

Publication number
CN110770252A
CN110770252A CN201780078161.4A CN201780078161A CN110770252A CN 110770252 A CN110770252 A CN 110770252A CN 201780078161 A CN201780078161 A CN 201780078161A CN 110770252 A CN110770252 A CN 110770252A
Authority
CN
China
Prior art keywords
seq
polypeptide
antibody
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078161.4A
Other languages
English (en)
Chinese (zh)
Inventor
T·K·萨巴齐
D·P·雷恩
黄丽安
许欣瑜
刘爱华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
National University of Singapore
Singapore Health Services Pte Ltd
Original Assignee
Agency for Science Technology and Research Singapore
National University of Singapore
Singapore Health Services Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore, National University of Singapore, Singapore Health Services Pte Ltd filed Critical Agency for Science Technology and Research Singapore
Publication of CN110770252A publication Critical patent/CN110770252A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780078161.4A 2016-10-17 2017-10-17 抗p53抗体 Pending CN110770252A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1617564.8 2016-10-17
GBGB1617564.8A GB201617564D0 (en) 2016-10-17 2016-10-17 Anti-p53 antibodies
PCT/SG2017/050522 WO2018074978A1 (en) 2016-10-17 2017-10-17 Anti-p53 antibodies

Publications (1)

Publication Number Publication Date
CN110770252A true CN110770252A (zh) 2020-02-07

Family

ID=57680660

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780078161.4A Pending CN110770252A (zh) 2016-10-17 2017-10-17 抗p53抗体

Country Status (7)

Country Link
US (3) US11613568B2 (enExample)
EP (1) EP3526251A4 (enExample)
JP (1) JP7173964B2 (enExample)
CN (1) CN110770252A (enExample)
GB (1) GB201617564D0 (enExample)
SG (1) SG11201903411YA (enExample)
WO (1) WO2018074978A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114574524A (zh) * 2022-03-14 2022-06-03 深圳市体内生物医药科技有限公司 一种从全基因组中筛选肝癌抑癌基因的方法及其应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110121268B (zh) * 2016-12-27 2023-01-31 希尔氏宠物营养品公司 宠物食品组合物
EP4077370A4 (en) * 2019-12-17 2024-02-28 The Johns Hopkins University MANA BODY TARGETING TUMOR ANTIGENS AND METHODS OF USE
GB202008688D0 (en) 2020-06-09 2020-07-22 Cancer Research Tech Ltd Chimeric antigen receptor cell
CN113403286B (zh) * 2021-06-24 2024-01-16 新乡学院 一种靶向性三展示噬菌体及其制备方法和应用
WO2023060115A1 (en) * 2021-10-05 2023-04-13 The Penn State Research Foundation Methods for treating cancers with mutated p53
CN116178501B (zh) * 2021-11-29 2025-08-29 深圳碳云智肽药物科技有限公司 靶向p53的多肽及其在制备用于治疗癌症的药物中的应用
EP4448583A4 (en) * 2021-12-16 2025-12-17 Univ Johns Hopkins MANABODIES AGAINST P53 TUMORANTIGENS AND METHOD FOR USE
TW202340474A (zh) * 2022-01-11 2023-10-16 大陸商深圳市珈鈺生物科技有限公司 樹突細胞腫瘤疫苗和其用途
WO2024178128A1 (en) * 2023-02-22 2024-08-29 Elysion Therapeutics, Inc. Lysis sensing receptors and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140058A (en) * 1992-11-26 2000-10-31 Newburn Ellis Activation of p53 protein
US20030086935A1 (en) * 1992-07-22 2003-05-08 Levine Arnold J. p53 vaccine
US20100074908A1 (en) * 2005-03-25 2010-03-25 Beka Solomon Human synthetic single-chain antibodies directed against the common epitope of mutant P53 and their uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083709A (en) 1985-08-21 2000-07-04 Osi Pharmaceuticals, Inc. Immunoassay for detection of mutant P53 polypeptide in serum
JP3179481B2 (ja) 1990-06-27 2001-06-25 プリンストン ユニバーシティ 突然変異体ｐ５３検出用プローブ
AU1370592A (en) 1991-02-01 1992-09-07 Oncogene Science, Inc. Immunoassay for detection of mutant p53 polypeptide in biological fluids
US5646016A (en) 1991-02-06 1997-07-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules
DE69333448D1 (en) * 1992-07-22 2004-04-15 Univ Princeton P53 impfstoff
US6630584B1 (en) 2000-03-16 2003-10-07 Ramot At Tel-Aviv University Ltd. Single chain antibody against mutant p53
WO2009112075A1 (en) * 2008-03-13 2009-09-17 Universita' Degli Studi Di Trieste Peptides and aptamers thereof as specific modulators of mutant p53 function
US8728479B2 (en) * 2009-03-31 2014-05-20 The Trustees Of The University Of Pennsylvania Antigen-binding proteins comprising recombinant protein scaffolds
SG11201401043SA (en) 2011-09-09 2014-08-28 Agency Science Tech & Res P53 activating peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030086935A1 (en) * 1992-07-22 2003-05-08 Levine Arnold J. p53 vaccine
US6140058A (en) * 1992-11-26 2000-10-31 Newburn Ellis Activation of p53 protein
US20100074908A1 (en) * 2005-03-25 2010-03-25 Beka Solomon Human synthetic single-chain antibodies directed against the common epitope of mutant P53 and their uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PHILIPPA J BARRELL等: "Expressing an antibacterial protein in bacteria for raising antibodies", 《PROTEIN EXPRESSION AND PURIFICATION》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114574524A (zh) * 2022-03-14 2022-06-03 深圳市体内生物医药科技有限公司 一种从全基因组中筛选肝癌抑癌基因的方法及其应用

Also Published As

Publication number Publication date
SG11201903411YA (en) 2019-05-30
US12195526B2 (en) 2025-01-14
GB201617564D0 (en) 2016-11-30
EP3526251A4 (en) 2020-06-10
WO2018074978A1 (en) 2018-04-26
US20230257457A1 (en) 2023-08-17
JP2019535241A (ja) 2019-12-12
JP7173964B2 (ja) 2022-11-16
EP3526251A1 (en) 2019-08-21
US20190248879A1 (en) 2019-08-15
US11613568B2 (en) 2023-03-28
US20250263475A1 (en) 2025-08-21

Similar Documents

Publication Publication Date Title
US12195526B2 (en) Anti-p53 antibodies
JP7755635B2 (ja) 抗ｈｅｒ２抗体
TWI821474B (zh) Ｃｄ３抗體及其藥物用途
KR102629403B1 (ko) Vista 항원 결합 분자
CN107530420B (zh) 抗tim-3抗体
JP6709215B2 (ja) 抗ｔｉｍ−３抗体
CN107438621B (zh) 抗pd-1抗体
CN112969476B (zh) 多特异性蛋白分子
WO2018137576A1 (zh) 抗pd-1单克隆抗体及其制备方法和应用
WO2019137397A1 (zh) Pd-l1抗体、其抗原结合片段及医药用途
WO2022007543A1 (zh) 一种抗fgl1抗体及其应用
WO2022143552A1 (zh) Pd-1结合分子及其应用
CN110092832A (zh) 抗ox40抗体及其用途
WO2021219127A1 (zh) 一种靶向her2和pd-1的双特异性抗体及其应用
WO2023025315A1 (zh) 抗b7-h3抗体、其制备方法及用途
CN116496396A (zh) 抗cd70纳米抗体及其用途
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
CN115873114A (zh) Ctla-4结合分子及其应用
WO2024188341A1 (zh) 特异性结合Claudin18.2的抗体及其制法和应用
CN121079322A (zh) 抗cd27单克隆抗体及其应用
CN110603267A (zh) 与p53-MHC I类复合物结合的T细胞受体样抗体
CN117510636B (zh) Gprc5d抗体及其应用
WO2011161970A1 (ja) 抗ｐｄｇｆ受容体抗体
CN110878122A (zh) 重组抗pd-l1单克隆抗体
WO2025214438A1 (zh) 结合cd19和/或cd22的抗原结合分子及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination